Pediatric Participation in Non-Therapeutic Research

Shaddy R. E. Denne S. C. , “The Committee on Drugs and Committee on Pediatric Research. Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations,” Pediatrics 125, no. 4 (2010): 850–860.

National Institutes of Health, Policy and Guidelines for the Inclusion of Children as Participants in Research Involving Human Subjects, 1998 Children's Health Act, Public Law 106–310 Sec. 1004, 2000.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Report and Recommendations: Research Involving Children, DHEW Publication No. (OS) 77–0004, Washington D.C., 1977, at 94–121.

Nelson R. M. , The Scientific and Ethical Path Forward in Pediatric Product Development, 2010, available at <http://www.bioethics.nih.gov/hsrc/slides/Nelson%20-%20NIH%20HSP%20Course%2010-20-2010.pdf>(last visited September 4, 2012).

Institute of Medicine and the National Academy, Field M. J. Behrman R. , eds., Ethical Conduct of Clinical Research Involving Children (Washington, D.C.: National Academy Press, 2004).

Id.;

Robinson W. M. , “Ethical Issues in Pediatric Research,” Journal of Clinical Ethics 11, no. 2 (2000): 145–150;

Kauffman R. E. , “Clinical Trials in Children: Problems and Pitfalls,” Paediatric Drugs 2, no. 6 (2000): 411–418;

Ross L. F. , “Do Healthy Children Deserve Greater Protection in Medical Research?” Journal of Pediatrics 142, no. 2 (2003): 108–112;

Freedman B. Fuks A. A. Weijer C. , “In Loco Parentis: Minimal Risk as an Ethical Threshold for Research upon Children,” Hastings Center Report 23, no. 2 (1993): 13–19;

Fisher C. B. Kornetsky S. Z. Prentice E. D. , “Determining Risk in Pediatric Research with No Prospect of Direct Benefit: Time for a National Consensus on the Interpretation of Federal Regulations,” American Journal of Bioethics 7, no. 3 (2007): 5–10.

See National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, supra note 3.

See Institute of Medicine et al., supra note 5;

Secretary's Advisory Committee on Human Research Protections (SACHRP), SACHRP Chair Letter to HHS Secretary Regarding Recommendations, 2005.

See Institute of Medicine et al.,; Council for International Organizations of Medical Sciences in collaboration with the World Health Organization, International Ethical Guidelines for Biomedical Research Involving Human Subjects, Geneva, 2002.

See Institute of Medicine et al., supra note 5.

Shah S. Whittle A. Wilfond B. Gensler G. Wendler D. , “How Do IRBs Apply the Federal Risk and Benefit Standards for Pediatric Research?” JAMA 291, no. 4 (2004): 476–482;

Janofsky J. B. Starfield B. , “Assessment of Risk in Research on Children,” Journal of Pediatrics 98, no. 5 (1981): 842–846.

Wendler D. Emanuel E. J. , “What Is a “Minor” Increase over Minimal Risk?” Journal of Pediatrics 147, no. 5 (2005): 575–578.

See Fisher , supra note 6.

See Freedman , supra note 6.

See Nelson , supra note 4;

Nelson R. M. Ross L. F. , “In Defense of a Single Standard of Research Risk for All Children,” Journal of Pediatrics 147, no. 5 (2005): 565–566;

Redmon R. B. , “How Minors Can Be Respected as Ends Yet Still Be Used as Subjects in Non-Therapeutic Research,” Journal of Medical Ethics 12, no. 2 (1986): 77–82.

Shah S. Whittle A. Wilfond B. Gensler G. Wendler D. , “How Do Institutional Review Boards Apply the Federal Risk and Benefit Standards for Pediatric Research?” JAMA 291, no. 4 (2004): 476–482.

Buchanan D. R. Miller F. G. , “Justice and Fairness in the Kennedy Krieger Institute Lead Paint Study: The Ethics of Public Health Research on Less Expensive, Less Effective Interventions,” American Journal of Public Health 96, no. 5 (2006): 781–787.

Slovic P. , “Perception of Risk,” Science 236, no. 4799 (1987): 280–285;

Tversky A. Kahnemen D. , “Judgment under Uncertainty: Heuristics and Biases,” Science 185, no. 415 (1974;): 1124–1131;

Weinstein N. D. , “Optimistic Biases about Personal Risks,” Science 246, no. 4935 (1989): 1232–1233.

Buchanan A. E. Brock D. W. , Deciding for Others: The Ethics of Surrogate Decision Making (Cambridge, NY: Cambridge University Press, 1989): At 123.

Ramsey P. , The Patient as Person (New Haven: Yale University Press, 1970).

Ramsey P. , “The Enforcement of Morals: Nontherapeutic Research on Children,” Hastings Center Report 6, no. 4 (1976): 21–30.

McCormick R. A. , “Experimentation in Children: Sharing in Sociality,” Hastings Center Report 6, no. 6):1976; 41–6.

Ackerman T. F. , “Moral Duties of Parents and Nontherapeutic Clinical Research Procedures Involving Children,” Bioethics Quarterly 2, no. 2 (1980): 94–111;

Ackerman T. F. , “Nontherapeutic Research Procedures Involving Chidlren with Cancer,” Journal of Pediatric Oncology Nursing 11, no. 3 (1994): 134–136.

See Redmon , supra note 15.

Nelson J. L. , “Taking Families Seriously,” Hastings Center Report 22, no. 4 (1992): 6–12.

Brendel D. H. Miller F. G. , “A Plea for Pragmatism in Clinical Research Ethics,” American Journal of Bioethics 8, no. 4 (2008): 24–31.

Hursthouse R. , “Normative Virtue Ethics,” in Crisp R. R. , ed., How Should One Live: Essays on the Virtues, Oxford Scholarship Online, 1998, available at <http://www.oxford-scholarship.com/view/10.1093/0198752342.001.0001/acprof-9780198752349>(last visited September 4, 2012).

See National Commission for the Protection of Human Subjects of Biomedical Research, supra note 3.

Iltis A. , “Pediatric Research Posing a Minor Increase over Minimal Risk and No Prospect of Direct Benefit: Challenging 45 CFR 46.406,” Accountability in Research 14, no. 1 (2007): 19–34.

See Ross , supra note 6.

Id.;

Ross L. F. , “Correspondence: Protecting Research Subjects,” New England Journal of Medicine 346, no. 26 (2002): 2093–2095;

Annas G. J. , “Questing for Grails: Duplicity, Betrayal and Self-Deception in Postmodern Medical Research: Contemporary Health Law and Policy,” Journal of Contemporary Health Law Policy 12, no. 2 (1996): 297–310;

Arkin L. M. Sondhi D. Worgall S. Hyon L. Suk L. H. K. Hackett N. R. , “Confronting the Issues of Therapeutic Misconception, Enrollment Decisions, and Personal Motives in Genetic Medicine-Based Clinical Research Studies for Fatal Disorders,” Human Gene Therapy 16, no. 9 (2005): 1028–1036;

Appelbaum P. S. , “The Therapeutic Misconception: Informed Consent in Psychiatric Research,” International Journal of Law and Psychiatry 5, nos. 3–4 (1982): 319–321.

Cerulo K. A. , “Identity Construction: New Issues, New Directions,” Annual Review of Sociology 23, (1997): 385–409;

Hoggett P. , Contested Communities: Experiences, Struggles, Policies (Bristol, England: The Policy Press, 1997);

Gusfield J. R. , The Community: A Critical Response (New York: Harper Colophon, 1975).

McMillan D. W. Chavis D. M. , “Sense of Community: A Definition and Theory,” Journal of Community Psychology 14, no. 1 (1986): 6–23;

Beem C. , The Necessity of Politics: Reclaiming American Public Life (Chicago: University of Chicago Press, 1999): At 20.

Tonnies F. , Community and Society (Gemeinschaft und Gesellschaft) (New Brunswick, NJ: Transaction Publishers, 1887/1988): At 22.

See Buchanan Brock , supra note 19, at 234;

Hardart G. E. Troug R. D. , “Attitudes and Preferences of Intensivists Regarding the Role of Family Interests in Medical Decision Making for Incompetent Patients,” Critical Care Medicine 31, no. 7 (2003): 1895–1900;

Hardart G. , “Including the Family's Interest in Medical Decision Making in Pediatrics,” Journal of Clinical Ethics 11, no. 2 (2000): 164–168;

Blustein J. , “The Family in Medical Decision-Making,” Hastings Center Report 23, no. 3 (1993): 6–13;

Hardwig J. , “The Problem of Proxies with Interests of Their Own: Toward a Better Theory of Proxy Decisions,” Journal of Clinical Ethics 4, no. 1 (1993): 20–27.

Schoeman F. , “Parental Discretion and Children's Rights: Background and Implications for Medical Decision-Making,” Journal of Medicine and Philospohy 10, no. 1 (1985): 45–61.

See National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, supra note 3;

see Institute of Medicine, supra note 5.

See Nelson , supra note 4.

See Annas , supra note 31;

see Arkin , supra note 31;

Ackerman T. F. , “The Ethics of Phase I Pediatric Oncology Trials,” IRB 17, no. 1 (1995): 1–5;

Oberman M. Frader J. , “Dying Children and Medical Research: Access to Clinical Trials as Benefit and Burden,” American Journal of Law & Medicine 29, nos. 2–3 (2003): 301–317.

See Annas , supra note 31;

see Arkin , supra note 31;

see Oberman Frader , supra note 39.